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Background
Transmission of HIV-1 across mucosal surfaces is the most
prevalent mode of viral infection. Therefore, a successful
vaccine must induce broad anti-viral immunity at the
mucosal surface. In the present study, we investigated the
immunogenicity of a novel Lactobacillus gasseri mucosal
vaccine vector for use in oral delivery of HIV antigens. L.
gasseri  was genetically engineered to express Salmonella
spp. flagellin (L. gasseri-FliC) – the agonist for Toll-like
receptor 5 (TLR5) and a potent activator of innate
immune cells.
Methods
To evaluate the potential adjuvant activity of our vector,
we determined the ability of L. gasseri-FliC to induce mye-
loid dendritic cell (DC) activation as measured by pheno-
typic activation and cytokine production. Briefly, myeloid
DCs were isolated and co-cultured with live L. gasseri
(w.t.),  L. gasseri-pTRK (empty plasmid), L. gasseri-FliC,
and Lactobacillus acidophilus, as well as TLR agonists rFliC
(TLR5) and rFLS-1 (TLR2/6). After 24 hours of co-culture,
cytokine production was analyzed via a 27-plex Luminex
assay and DC phenotype determined through flow cytom-
etry.
Results
Each Lactobacillus treatment induced a unique response
from the DCs regardless of strain, though different from
purified TLR agonists alone. All treatment groups yielded
higher surface concentrations of CD86 than CD80
amongst populations of CD80+CD86+HLAII+ DCs, but
only L. acidophilus, L. gasseri-FliC, and rFliC induced sig-
nificant increases in the overall percent of DCs expressing
co-stimulatory molecules. Elevated levels of cytokines
IL10, IL1RA, IFNγ, IL6, TNFα, IL1β, GM-CSF, G-CSF, and
chemokines IL8, MIP1α, MIP1β were produced by Lacto-
bacillus-pulsed DCs. IL12, IL2 and IL15 were produced in
minimal concentrations, with the IL10:IL12 ratio being
100-fold greater than that of TLR agonists alone.
Conclusion
These results suggest DC phenotypic maturation is signif-
icantly affected by Lactobacillus treatment and immuno-
logical recruitment is likely, but the functional
significance of the mixed inflammatory and anti-inflam-
matory cytokine profile must be evaluated in vivo to
include the immunological perspective of the mucosa.
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